Boylan James P 4

What Happened

• James P. Boylan, a director of Immunome, was granted a derivative award of 9,897 shares on June 10, 2026. The award is reported at an exercise/vesting price of $0.00 (total reported value $0) and is recorded as a derivative instrument (an option).

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely filing).
• Award: 9,897 shares; reported price $0.00; classified as a derivative (option).
• Vesting: vests in four equal quarterly installments beginning June 10, 2026 and continuing through the one‑year anniversary (quarterly vesting subject to continuous service).
• Ownership after transaction: Mr. Boylan has agreed to receive and hold the securities for the benefit of Enavate Sciences, LP and disclaims beneficial ownership and all right, title and interest in the reported securities — the filing does not report personal beneficial ownership by Mr. Boylan.
• No sale or cashless exercise reported; this is a grant/award, not a disposition.

Context

• This is a director compensation grant (an option-style award) that will vest quarterly; because the award is being held for the benefit of Enavate Sciences, LP and Boylan disclaims beneficial ownership, the economic ownership likely resides with that entity rather than with Boylan personally. Grants to directors are common and do not by themselves indicate a buy/sell market signal.